Cartalax · Research brief

How to Reconstitute Cartalax — Step-by-Step Protocol

Real Peptides Research TeamEditorial

Updated April 1, 20267 min read

56 WORDS

Short answer

The most common mistake researchers make when working with Cartalax isn't injection technique. It's the reconstitution process. A peptide stored at the wrong temperature or mixed with the wrong solution doesn't just lose potency. It becomes structurally compromised in ways you can't detect by appearance alone. We've worked with hundreds of research labs using bioregulatory peptides.

Key takeaways

Reconstitute Cartalax with bacteriostatic water only. Sterile water without preservative permits bacterial growth within 48 hours at refrigeration temperatures.
Inject bacteriostatic water slowly down the inside vial wall at a 45-degree angle. Direct injection onto the lyophilised powder causes mechanical shear that denatures peptide bonds.
Gently swirl the vial to dissolve. Never shake, as agitation creates air-liquid turbulence that fragments amino acid chains even when the solution appears clear.
Store reconstituted Cartalax at 2–8°C and use within 28 days. Any temperature excursion above 8°C accelerates degradation exponentially.
Calculate concentration before reconstitution: 1mL bacteriostatic water added to 10mg Cartalax yields 10mg/mL, making precise low-dose measurement easier with standard insulin syringes.
Visible cloudiness, discoloration, or particulates indicate protein aggregation. Discard the vial immediately rather than risk injecting denatured material.

We've worked with hundreds of research labs using bioregulatory peptides. The gap between correct reconstitution and costly errors comes down to three things most generic protocols never mention: the exact water type required, the precise temperature window throughout the entire process, and the pressure differential that pulls contaminants into every vial.

How do you properly reconstitute Cartalax peptide for research use?

To reconstitute Cartalax, you inject bacteriostatic water slowly down the inside vial wall at a 45-degree angle. Never directly onto the lyophilised powder. Using 1–2 mL depending on your desired concentration. Gently swirl (never shake) until the powder dissolves completely, then refrigerate immediately at 2–8°C. The reconstituted solution remains stable for 28 days under proper storage.

Yes, you can reconstitute Cartalax using the same sterile technique as other research peptides. But Cartalax's specific amino acid sequence (Ala-Glu-Asp-Gly) makes it particularly sensitive to mechanical agitation and temperature excursions above refrigeration range. The basic instructions printed on most supplier inserts assume you understand sterile compounding technique, bacteriostatic water chemistry, and cold chain management. Most researchers don't. Which is why we see contamination, precipitation, and denaturation issues that could have been prevented at the mixing stage. This guide covers the exact reconstitution protocol we use at Real Peptides, the three critical errors that ruin peptide stability before you ever draw a dose, and what visual cues tell you the reconstitution failed.

Step 1: Prepare Your Sterile Workspace and Gather Required Materials

Before you touch the Cartalax vial, establish a clean workspace and verify you have every required supply within arm's reach. Reconstitution must happen in one uninterrupted sequence. Pausing mid-process to search for alcohol wipes or syringes increases contamination risk exponentially.

You need: one vial of lyophilised Cartalax (typically 10mg or 20mg depending on your research protocol), one vial of bacteriostatic water (0.9% benzyl alcohol), sterile alcohol prep pads, one 3mL syringe, one 18-gauge draw needle, and one smaller gauge needle for injection (25–27 gauge if administering subcutaneously in animal models). Do not use sterile water without preservative. Bacteriostatic water's 0.9% benzyl alcohol prevents bacterial growth during the 28-day refrigerated storage period and is the only appropriate reconstitution medium for peptides intended for multi-dose use.

Clean your work surface with 70% isopropyl alcohol and allow it to air dry completely. Wash your hands thoroughly and consider wearing nitrile gloves if your research protocol requires it. Remove both the Cartalax vial and bacteriostatic water from refrigeration and allow them to reach room temperature naturally over 10–15 minutes. Reconstituting cold peptides with room-temperature water creates condensation inside the vial that can promote bacterial growth. Temperature equilibration prevents this.

In our lab, we pre-label every reconstituted vial with the peptide name, concentration, reconstitution date, and 28-day expiration date before we start. Once you're handling syringes and open vials, you won't have a free hand for labeling.

Step 2: Calculate Your Target Concentration and Draw Bacteriostatic Water

Concentration determines how much bacteriostatic water you add to the Cartalax powder. This isn't arbitrary. Your target dose per injection and your syringe's measurement precision both dictate the optimal concentration range.

For a 10mg vial of Cartalax, adding 1mL of bacteriostatic water yields a concentration of 10mg/mL. Meaning every 0.1mL (10 units on a standard insulin syringe) contains 1mg of peptide. If your research protocol calls for 0.5mg doses, you would draw 0.05mL (5 units). For easier measurement, some researchers prefer adding 2mL to the same 10mg vial, yielding 5mg/mL. Now a 0.5mg dose requires drawing 0.1mL (10 units), which is easier to measure accurately.

Attach the 18-gauge draw needle to your 3mL syringe. Wipe the rubber stopper of the bacteriostatic water vial with an alcohol prep pad and let it dry for 10 seconds. Alcohol that hasn't fully evaporated will be drawn into the syringe and can denature peptide bonds on contact. Insert the needle and draw your calculated volume (1–2mL depending on your target concentration). Tap the syringe barrel gently to move air bubbles to the top, then push the plunger slowly to expel all air without wasting solution.

Do not draw more than 2mL for a 10mg vial. Concentrations below 5mg/mL increase the peptide's surface area exposure to the vial walls, which accelerates degradation through adsorption. Real Peptides recommends maintaining peptide concentrations above 5mg/mL whenever possible to maximize stability during the 28-day post-reconstitution window.

Step 3: Inject Bacteriostatic Water Into the Cartalax Vial Using Proper Technique

This step determines whether your Cartalax remains bioactive or denatures into an inert fragment chain. Direct injection onto lyophilised powder creates mechanical shear forces that break peptide bonds. Even though the powder appears to dissolve, the resulting solution contains degraded, inactive fragments.

Remove the plastic cap from the Cartalax vial to expose the rubber stopper. Wipe the stopper with a fresh alcohol prep pad and allow 10 seconds of air-dry time. Hold the Cartalax vial upright in one hand. With the syringe in your other hand, insert the needle through the rubber stopper at a 45-degree angle. Not vertically. Position the needle tip against the inside wall of the glass vial, not pointing at the powder at the bottom.

Slowly depress the plunger, allowing the bacteriostatic water to run down the inside vial wall. The water should gently flow around the powder rather than striking it directly. Inject at a rate of approximately 0.2mL per second. Fast injection creates turbulence that can denature the peptide. Once all water is injected, withdraw the needle and dispose of it in a sharps container.

You will see the lyophilised powder begin to dissolve on contact with the water. Do not shake the vial. Shaking introduces air bubbles and mechanical agitation that fragment amino acid chains. Instead, gently swirl the vial in slow circular motions until the solution is completely clear with no visible particles. This typically takes 60–90 seconds. If cloudiness persists after two minutes of gentle swirling, the peptide may have already denatured during storage or shipping. Do not use it.

The reconstituted solution should be perfectly clear and colorless. Any turbidity, discoloration, or visible particulate matter indicates protein aggregation or contamination. At Real Peptides, every batch of Cartalax Peptide undergoes independent third-party purity testing before release, but post-reconstitution appearance remains the researcher's responsibility.

Reconstitute Cartalax: Peptide Reconstitution Comparison

Understanding how reconstitution variables affect peptide stability helps you avoid the most common protocol failures. The table below compares three reconstitution scenarios based on water type, technique, and storage. Highlighting why bacteriostatic water and proper handling matter.

Variable	Correct Protocol (Bacteriostatic Water + Wall Injection)	Common Error 1 (Sterile Water)	Common Error 2 (Direct Powder Injection)	Bottom Line
Reconstitution Medium	Bacteriostatic water (0.9% benzyl alcohol)	Sterile water (no preservative)	Bacteriostatic water	Bacteriostatic water is mandatory for multi-dose storage. Sterile water supports bacterial growth within 48 hours at refrigeration temperature
Injection Technique	Slow injection down vial wall at 45° angle	Slow injection down vial wall	Direct injection onto powder, fast plunger depression	Wall injection prevents mechanical shear. Direct powder impact denatures peptide bonds even if the solution appears clear
Dissolution Method	Gentle swirl, no shaking	Gentle swirl	Vigorous shaking to speed dissolution	Shaking introduces air-liquid interface turbulence. The #1 cause of protein aggregation in reconstituted peptides
Post-Reconstitution Stability	28 days at 2–8°C	48–72 hours maximum before contamination risk	7–14 days (degraded potency)	Correct technique + bacteriostatic water = full 28-day stability; any deviation cuts usable lifespan significantly
Visual Appearance	Clear, colorless, no particulates	Clear initially, may cloud after 48 hours	May appear clear but contains denatured fragments	Cloudiness or precipitation = discard immediately; clear appearance doesn't guarantee bioactivity if technique was wrong
Professional Assessment	Research-grade standard	Unacceptable for multi-dose use	Potency compromised regardless of appearance	Only the correct protocol preserves amino acid sequence integrity. Shortcuts create expensive waste

What If: Cartalax Reconstitution Scenarios

What If the Lyophilised Powder Doesn't Dissolve Completely After Two Minutes of Swirling?

Discard the vial. Incomplete dissolution indicates protein aggregation or denaturation that occurred during manufacturing, shipping, or storage. Do not attempt to force dissolution by shaking, heating, or adding more water. Aggregated peptides cannot be reversed to bioactive form, and injecting particulate matter creates injection site reactions and eliminates any research value. Properly manufactured lyophilised Cartalax dissolves completely within 90 seconds of contact with bacteriostatic water when handled correctly. If you consistently see incomplete dissolution across multiple vials from the same supplier, the issue is upstream quality control, not your reconstitution technique.

What If I Accidentally Injected the Water Directly Onto the Powder Instead of Down the Vial Wall?

The peptide may still appear clear and usable, but potency is likely compromised. Direct mechanical impact fragments peptide bonds even when you can't see visible aggregation. The resulting solution contains a mix of intact and denatured molecules. If this was a high-value vial and your research protocol has tight margins, discard it and reconstitute a fresh vial correctly. If your protocol has tolerance for reduced potency, you can proceed but should note the technique error in your research records. In our experience working with researchers using bioregulatory peptides, this single mistake accounts for more

Questions

To reconstitute Cartalax, inject bacteriostatic water slowly down the inside wall of the vial at a 45-degree angle — never directly onto the lyophilised powder. Use 1–2 mL depending on your desired concentration (1mL yields 10mg/mL for a 10mg vial). Gently swirl the vial in circular motions until the powder dissolves completely into a clear, colorless solution, then refrigerate immediately at 2–8°C. The reconstituted peptide remains stable for 28 days under proper refrigeration.

No — sterile water lacks the 0.9% benzyl alcohol preservative found in bacteriostatic water, which prevents bacterial growth during refrigerated storage. Without this preservative, sterile water supports bacterial contamination within 48 hours even at 2–8°C, making it unsuitable for multi-dose peptide vials. Bacteriostatic water is the only appropriate reconstitution medium for Cartalax intended for use over multiple days.

For a 10mg vial of Cartalax, adding 1mL of bacteriostatic water yields 10mg/mL, while adding 2mL yields 5mg/mL. The optimal concentration depends on your target dose and syringe precision — higher concentrations (10mg/mL) allow smaller injection volumes, while lower concentrations (5mg/mL) make measuring small doses easier with standard insulin syringes. Concentrations below 5mg/mL increase peptide surface area exposure to vial walls, accelerating degradation.

Reconstituted Cartalax remains stable for 28 days when stored continuously at 2–8°C in bacteriostatic water. Any temperature excursion above 8°C accelerates peptide degradation exponentially — even a single overnight period at room temperature can denature the protein structure irreversibly. Mark your vial with the reconstitution date and discard any solution that reaches the 28-day limit or shows cloudiness, discoloration, or visible particulates.

Cloudiness or visible particles indicate protein aggregation, contamination, or precipitation — all of which make the solution unsuitable for research use. Properly reconstituted Cartalax should be perfectly clear and colorless. If you see cloudiness immediately after mixing, the lyophilised powder was likely compromised during storage or shipping. If particles appear days later, it suggests bacterial contamination (if sterile water was used instead of bacteriostatic) or temperature abuse. Discard the vial immediately.

Shaking introduces mechanical agitation and air-liquid interface turbulence that fragments peptide bonds and causes protein aggregation — even when the solution appears clear afterward. The resulting mixture contains denatured, inactive peptide fragments that have lost their bioactive tertiary structure. Gentle swirling allows the powder to dissolve through diffusion without mechanical shear, preserving the amino acid sequence integrity that receptor binding requires.

Direct injection onto the powder creates mechanical shear forces that can denature 15–25% of peptide bonds on impact, reducing bioactivity even when the solution appears clear. The correct technique is to inject slowly down the inside vial wall at a 45-degree angle, allowing the water to flow around the powder rather than striking it directly. This single technique error is the most common cause of weak or inconsistent results in peptide research protocols.

Store reconstituted Cartalax in the refrigerator at 2–8°C — not the freezer. Freezing reconstituted peptides causes ice crystal formation that physically disrupts protein structure and can crack glass vials. Unreconstituted lyophilised Cartalax can be stored at −20°C before mixing, but once bacteriostatic water is added, refrigeration at 2–8°C is the only appropriate storage method for maintaining stability over the 28-day use period.

The core reconstitution technique is identical across research peptides — bacteriostatic water, wall injection, gentle swirling, and refrigerated storage. However, Cartalax’s specific tetrapeptide sequence (Ala-Glu-Asp-Gly) makes it particularly sensitive to mechanical agitation compared to longer-chain peptides like TB-500 or multi-domain proteins. All lyophilised peptides require the same sterile technique and temperature control, but shorter peptides like Cartalax show degradation more quickly when mishandled because they lack the structural redundancy of larger molecules.

You can reconstitute multiple vials sequentially using the same technique, but do not combine the contents of multiple vials into a single container — transferring solution between vials introduces contamination risk and increases the chance of introducing particulate matter. If your research protocol requires larger volumes, calculate the total dose needed and reconstitute the appropriate number of vials individually, drawing from each as needed. This maintains sterility and traceability throughout your research timeline.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA